
**Availability of Antimalarials and Malaria Diagnostics:**

Changes in first-line Artemisinin Combination Therapy (ACT) availability over time reflect changes in national guidelines and procurement challenges in 2010/2011.

In 2009, 20% of the private sector was stocking oral artemisinin mono-therapies. In 2013 this figure had fallen to <1%.

In 2013, availability of malaria diagnosis remains high in the public sector. Private sector availability is lower (~50%).

**In 2013, private sector providers sold ACT for $1.50 and RDT for $1:** There is a financial incentive to get tested prior to treatment.

**Market Share:** By 2013, ACT capture 87% of the total antimalarial market share.

652 (2009); 1,001 (2011); 792 (2013) = N. of ANTIMALARIOAL STOCKING OUTLETS